(IRF5) Interactome: Investigating the Role of Co-Factors in Regulation of Inflammation

Total Page:16

File Type:pdf, Size:1020Kb

(IRF5) Interactome: Investigating the Role of Co-Factors in Regulation of Inflammation The Interferon Regulatory Factor 5 (IRF5) Interactome: Investigating the role of co-factors in regulation of inflammation Hayley Eames Supervisors: Prof. Irina A. Udalova Dr. Robin Wait A thesis submitted for the degree of Doctor of Philosophy at the Kennedy Institute of Rheumatology Faculty of Medicine Imperial College London September 2013 Abstract Interferon Regulatory Factor 5 (IRF5) is a key transcription factor that regulates inflammatory responses by acting as a mediator of macrophage plasticity. IRF5 is expressed at high levels in pro-inflammatory (M1) macrophages where it drives expression of characteristic M1 markers, such as IL-12p40, IL-12p35 and IL-23p19, and inhibits expression of typical markers of anti-inflammatory (M2) macrophages, like IL-10. In this way, IRF5 polarises macrophages towards a pro-inflammatory phenotype. There are two modes of IRF5 activity: 1) direct binding to Interferon Stimulated Response Element (ISRE) sites in the DNA, and 2) indirect recruitment via protein- protein interactions. IRF5 can be indirectly recruited via interactions with the RelA subunit of Nuclear Factor kappa B (NFκB) at multiple inflammatory loci genome- wide, including Tnf. This suggests protein-protein interactions between the two factors are of great importance for driving inflammatory gene expression. My research shows the IRF Association Domain (IAD) of IRF5 and the Dimerisation Domain (DD) of RelA form an interaction interface between the two proteins. I have identified a short peptide, a region of IRF5 IAD sequence, that can bind to RelA, and hypothesise this peptide could block IRF5-RelA interactions, potentially dampening expression of inflammatory mediators co-regulated by these two factors. I have also identified a novel co-factor of IRF5: Krüppel Associated Protein 1 (KAP1) by a proteomic screen consisting of affinity purification coupled to mass spectrometry. The IRF5-KAP1 complex is present in M1 macrophages, and absence of KAP1 in this cell type results in prolonged TNF secretion, suggesting that KAP1 is important for ‘switching off’ Tnf gene expression. Further investigation showed KAP1 is important for regulation of a heterochromatin (H3K9me3) environment downstream of the Tnf locus. By understanding the IRF5 interactome, we hope to unravel and potentially manipulate the determinants of IRF5’s key role in inflammation in a cell-type and activity-specific manner. 2 Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or distribution, researchers must make it clear to others the licence terms of this work. All experimental data described in this thesis are original and have been performed by myself, except for the data described in the Figures mentioned below, which were performed by or with great help from others. Mass spectrometry (LC-MS/MS) and trypsin digestion of protein bands in Figures 3.5, 3.15. 3.16 and Supplementary Figure S9.1 were performed either by Dr Robin Wait (Kennedy Institute of Rheumatology) or Dr Mike Deery and his team (Cambridge Centre for Proteomics, University of Cambridge). Dr David Saliba (Udalova Group, Kennedy Institute of Rheumatology) performed the Flag-immunoprecipitation in Figure 5.8, One-Strep affinity purification in Figure 3.16, and the ChIP-seq study referred to in Chapter 5. Dr Pavel Savitsky performed RelA protein purification for Figure 5.18 and the associated bio-layer interferometry was performed with great help from Dr Oleg Fedorov (both from the Structural Genomics Consortium, University of Oxford). This work has been carried out at the Kennedy Institute of Rheumatology and was funded by Arthritis Research UK, Medical Research Council, the European Community Seventh Framework Programme FP7/2007-2013 and the Kennedy Institute trustees. Hayley Eames (September 2013) 3 Acknowledgements First and foremost, I would like to thank my supervisor Prof. Irina Udalova for her fantastic support, guidance and the opportunity to work on a truly interesting project. Thanks also to Dr. Robin Wait for his proteomics expertise in the early stages of this project. Additionally, I would like to say a very big thank you to Dr. David Saliba, who I have considered to be an ‘honorary supervisor’ since day one, and deserves a lot of credit for my improved laboratory ability. He has always been my first point-of-call for technical discussion, and has been a great source of entertainment in the lab, particularly on long days full of many, many ChIP washes! In term of reagents and expertise, I would like to extend my gratitude to Dr. Tim Smallie, Dr. Alexey Ivanov and Prof. Betsy Barnes for their kind gifts of expression constructs, Dr Mike Deery and his team at the Cambridge Centre for Proteomics for mass spectrometry, and Dr. Oleg Fedorov and Dr Pavel Savitsky at the Structural Genomics Consortium for protein purification and bio-layer interferometry. This project would also not have been possible without the help of many people at the Kennedy Institute of Rheumatology, including the trustees, who have funded this research and built us an amazing new building in Oxford. I would like to thank Katrina Blazek – the unofficial boss of the Udalova group – for her incredible organisation, love of tea breaks, and for being a friendly face in the laboratory even at weekends. Katrina has maintained our mouse colonies, is very skilled at bone marrow extraction from femurs, and patiently taught me how to scruff a mouse. Thanks also to Alessandra Lanfrancotti, who has always been a great help to the Udalova group, in particular aiding in elutriation and adenovirus purification. A special mention to Dr. Grigory Ryzhakov, who can suggest an answer to anything, and I’m pretty sure has everything cloned into an expression plasmid! A big thank you to the rest of the Udalova group, past and present – Miriam, Thomas, Adam, Scott, Fergie, Matt, Lynn – and to all the other brilliant members of the London ground floor laboratory for both discussion and giggles. I would like to thank Dr. Will Wood, my undergraduate dissertation supervisor, for giving me the confidence to apply for a PhD project, Sue Boyce at GSK for introducing me to techniques that I routinely use today, and my parents for their constant support and encouragement. To Aaron, thanks for putting up with me when I’m grumpy after a long commute home from London, and it looks like I won the thesis-writing race! Xxx 4 Table of Contents ABSTRACT ..................................................................................................... 2 DECLARATION ............................................................................................... 3 ACKNOWLEDGEMENTS ............................................................................... 4 TABLE OF CONTENTS .................................................................................. 5 LIST OF FIGURES ........................................................................................ 10 LIST OF TABLES .......................................................................................... 12 LIST OF SUPPLEMENTARY FIGURES ....................................................... 12 1.0 – INTRODUCTION .................................................................................. 14 1.1 – THE IMMUNE SYSTEM ............................................................................... 14 1.1.1 – Innate Immune Responses .................................................................... 14 1.1.1.1 – Cellular Innate Immunity ................................................................. 15 1.1.1.2 – Humoral Innate Immunity ................................................................ 16 1.1.2 – Cells of the innate immune system ........................................................ 16 1.1.2.1 – Monocytes ...................................................................................... 16 1.1.2.2 – Macrophages .................................................................................. 17 1.1.2.3 – Dendritic cells ................................................................................. 19 1.1.2.4 – NK cells ........................................................................................... 20 1.1.2.5 – Granulocytes ................................................................................... 20 1.1.3 – Activation of adaptive immunity by innate immunity .............................. 21 1.1.3.1 – T-cell-mediated adaptive immunity ................................................. 21 1.1.3.2 – B-cell-mediated adaptive immunity ................................................. 22 1.2 – REGULATION OF MACROPHAGE GENE EXPRESSION ......................... 24 1.2.1 – Role of PU.1 and epigenetics in macrophage gene expression ............ 25 1.2.2 – Nuclear Factor kappa B (NFκB) family of transcription factors .............. 26 1.3 – TRANSCRIPTIONAL ACTIVITY OF IRFS IN MACROPHAGES ................ 27 1.3.1 - The IRF family of transcription factors .................................................... 28 1.3.2 - IRF1/IRF2: Positive and negative regulators of gene expression .......... 30 1.3.2.1 - IRF1 positively regulates gene expression in macrophages ........... 30 1.3.2.2 - IRF2 can antagonise and co-operate with
Recommended publications
  • Microglia Emerge from Erythromyeloid Precursors Via Pu.1- and Irf8-Dependent Pathways
    ART ic LE S Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways Katrin Kierdorf1,2, Daniel Erny1, Tobias Goldmann1, Victor Sander1, Christian Schulz3,4, Elisa Gomez Perdiguero3,4, Peter Wieghofer1,2, Annette Heinrich5, Pia Riemke6, Christoph Hölscher7,8, Dominik N Müller9, Bruno Luckow10, Thomas Brocker11, Katharina Debowski12, Günter Fritz1, Ghislain Opdenakker13, Andreas Diefenbach14, Knut Biber5,15, Mathias Heikenwalder16, Frederic Geissmann3,4, Frank Rosenbauer6 & Marco Prinz1,17 Microglia are crucial for immune responses in the brain. Although their origin from the yolk sac has been recognized for some time, their precise precursors and the transcription program that is used are not known. We found that mouse microglia were derived from primitive c-kit+ erythromyeloid precursors that were detected in the yolk sac as early as 8 d post conception. + lo − + − + These precursors developed into CD45 c-kit CX3CR1 immature (A1) cells and matured into CD45 c-kit CX3CR1 (A2) cells, as evidenced by the downregulation of CD31 and concomitant upregulation of F4/80 and macrophage colony stimulating factor receptor (MCSF-R). Proliferating A2 cells became microglia and invaded the developing brain using specific matrix metalloproteinases. Notably, microgliogenesis was not only dependent on the transcription factor Pu.1 (also known as Sfpi), but also required Irf8, which was vital for the development of the A2 population, whereas Myb, Id2, Batf3 and Klf4 were not required. Our data provide cellular and molecular insights into the origin and development of microglia. Microglia are the tissue macrophages of the brain and scavenge dying have the ability to give rise to microglia and macrophages in vitro cells, pathogens and molecules using pattern recognition receptors and in vivo under defined conditions.
    [Show full text]
  • KLF2 Induced
    UvA-DARE (Digital Academic Repository) The transcription factor KLF2 in vascular biology Boon, R.A. Publication date 2008 Link to publication Citation for published version (APA): Boon, R. A. (2008). The transcription factor KLF2 in vascular biology. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:23 Sep 2021 Supplementary data: Genes induced by KLF2 Dekker et al. LocusLink Accession Gene Sequence Description Fold p-value ID number symbol change (FDR) 6654 AK022099 SOS1 cDNA FLJ12037 fis, clone HEMBB1001921. 100.00 5.9E-09 56999 AF086069 ADAMTS9 full length insert cDNA clone YZ35C05. 100.00 1.2E-09 6672 AF085934 SP100 full length insert cDNA clone YR57D07. 100.00 6.7E-13 9031 AF132602 BAZ1B Williams Syndrome critical region WS25 mRNA, partial sequence.
    [Show full text]
  • The Transcription Factors C-Myb and GATA-2 Act Independently in The
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 5313-5318, May 1996 Medical Sciences The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis PAOLA MELOTrl AND BRUNO CALABRETTA Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107 Communicated by Sidney Weinhouse, Thomas Jefferson University, Philadelphia, PA, January 23, 1996 (received for review, October 20, 1995) ABSTRACT The transcription factors c-myb and GATA-2 erythromyeloid differentiation (7). This process appears to are both required for blood cell development in vivo and in rest in the ability of c-myb to activate the expression of vitro. However, very little is known on their mechanism(s) of hematopoiesis-specific targets such as c-kit,flt-3, GATA-1, and action and whether they impact on complementary or over- CD34, but not GATA-2 (7). The induction of c-kit and flt-3 lapping pathways of hematopoietic proliferation and differ- expression and the dependence of c-myb-transfected ES cells entiation. We report here that embryonic stem (ES) cells on the expression of these cytokine receptors for their prolif- transfected with c-myb or GATA-2 cDNAs, individually or in eration (7) strongly suggest that the up-regulation of growth combination, underwent hematopoietic commitment and dif- factor receptor levels is of fundamental importance for the ferentiation in the absence of added hematopoietic growth expansion of progenitor cells. In turn, such a process is factors but that stimulation with c-kit and flt-3 ligands en- probably a requirement for completion of the differentiation hanced colony formation only in the c-myb transfectants.
    [Show full text]
  • Comprehensive Study of Nuclear Receptor DNA Binding Provides a Revised Framework for Understanding Receptor Specificity
    ARTICLE https://doi.org/10.1038/s41467-019-10264-3 OPEN Comprehensive study of nuclear receptor DNA binding provides a revised framework for understanding receptor specificity Ashley Penvose 1,2,4, Jessica L. Keenan 2,3,4, David Bray2,3, Vijendra Ramlall 1,2 & Trevor Siggers 1,2,3 The type II nuclear receptors (NRs) function as heterodimeric transcription factors with the retinoid X receptor (RXR) to regulate diverse biological processes in response to endogenous 1234567890():,; ligands and therapeutic drugs. DNA-binding specificity has been proposed as a primary mechanism for NR gene regulatory specificity. Here we use protein-binding microarrays (PBMs) to comprehensively analyze the DNA binding of 12 NR:RXRα dimers. We find more promiscuous NR-DNA binding than has been reported, challenging the view that NR binding specificity is defined by half-site spacing. We show that NRs bind DNA using two distinct modes, explaining widespread NR binding to half-sites in vivo. Finally, we show that the current models of NR specificity better reflect binding-site activity rather than binding-site affinity. Our rich dataset and revised NR binding models provide a framework for under- standing NR regulatory specificity and will facilitate more accurate analyses of genomic datasets. 1 Department of Biology, Boston University, Boston, MA 02215, USA. 2 Biological Design Center, Boston University, Boston, MA 02215, USA. 3 Bioinformatics Program, Boston University, Boston, MA 02215, USA. 4These authors contributed equally: Ashley Penvose, Jessica L. Keenan. Correspondence
    [Show full text]
  • Homeobox Gene Expression Profile in Human Hematopoietic Multipotent
    Leukemia (2003) 17, 1157–1163 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development T Taghon1, K Thys1, M De Smedt1, F Weerkamp2, FJT Staal2, J Plum1 and G Leclercq1 1Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium; and 2Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands Class I homeobox (HOX) genes comprise a large family of implicated in this transformation proces.14 The HOX-C locus transcription factors that have been implicated in normal and has been primarily implicated in lymphomas.15 malignant hematopoiesis. However, data on their expression or function during T-cell development is limited. Using degener- Hematopoietic cells are derived from stem cells that reside in ated RT-PCR and Affymetrix microarray analysis, we analyzed fetal liver (FL) in the embryo and in the adult bone marrow the expression pattern of this gene family in human multipotent (ABM), which have the unique ability to self-renew and thereby stem cells from fetal liver (FL) and adult bone marrow (ABM), provide a life-long supply of blood cells. T lymphocytes are a and in T-cell progenitors from child thymus. We show that FL specific type of hematopoietic cells that play a major role in the and ABM stem cells are similar in terms of HOX gene immune system. They develop through a well-defined order of expression, but significant differences were observed between differentiation steps in the thymus.16 Several transcription these two cell types and child thymocytes.
    [Show full text]
  • IRF5 Gene Interferon Regulatory Factor 5
    IRF5 gene interferon regulatory factor 5 Normal Function The protein produced from the IRF5 gene, called interferon regulatory factor 5 (IRF5), acts as a transcription factor, which means that it attaches (binds) to specific regions of DNA and helps control the activity of certain genes. When a virus is recognized in the cell, the IRF5 gene is turned on (activated), which leads to the production of IRF5 protein. The protein binds to specific regions of DNA that regulate the activity of genes that produce interferons and other cytokines. Cytokines are proteins that help fight infection by promoting inflammation and regulating the activity of immune system cells. In particular, interferons control the activity of genes that help block the replication of viruses, and they stimulate the activity of certain immune system cells known as natural killer cells. Health Conditions Related to Genetic Changes Systemic scleroderma Several normal variations in the IRF5 gene have been associated with an increased risk of developing systemic scleroderma, which is an autoimmune disorder characterized by the buildup of scar tissue (fibrosis) in the skin and internal organs. Although the IRF5 gene is known to stimulate the immune system in response to viruses, it is unknown how the gene variations contribute to the increased risk of systemic scleroderma. Researchers believe that a combination of genetic and environmental factors may play a role in development of the condition. Rheumatoid arthritis MedlinePlus Genetics provides information about Rheumatoid arthritis Systemic lupus erythematosus MedlinePlus Genetics provides information about Systemic lupus erythematosus Ulcerative colitis MedlinePlus Genetics provides information about Ulcerative colitis Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 1 Autoimmune disorders Studies have associated normal variations in the IRF5 gene with an increased risk of several autoimmune disorders.
    [Show full text]
  • Cells Transformed by a V-Myb-Estrogen Receptor Fusion Differentiate Into Multinucleated Giant Cells
    JOURNAL OF VIROLOGY, May 1997, p. 3760–3766 Vol. 71, No. 5 0022-538X/97/$04.0010 Copyright q 1997, American Society for Microbiology Cells Transformed by a v-Myb-Estrogen Receptor Fusion Differentiate into Multinucleated Giant Cells UTE ENGELKE, DUEN-MEI WANG, AND JOSEPH S. LIPSICK* Department of Pathology, Stanford University School of Medicine, Stanford, California 94305-5324 Received 22 October 1996/Accepted 29 January 1997 In order to make conditional alleles of the v-myb oncogene, we constructed and tested avian retroviruses which produce a number of different fusion proteins between v-Myb and the human estrogen receptor (ER). We found that the portion of the ER used in making these fusions profoundly affected their transcriptional activation. However, all the fusions tested were only weakly transforming in embryonic yolk sac assays and there was no direct correlation between the level of transcriptional activation and strength of oncogenic transformation. Nevertheless, transformation by a v-Myb-ER fusion was estrogen dependent, and upon with- drawal of the hormone, monocytic-lineage cells differentiated into multinucleated giant cells. Surprisingly, the withdrawal of estrogen caused a dramatic increase in the stability of the fusion protein, although it remained unable to promote cell growth or block differentiation. Conditional alleles of retroviral oncogenes have provided genes, have been isolated and analyzed in considerable detail powerful tools with which to dissect the mechanism of onco- (3, 4). A differential cDNA screen has identified a target gene, genic transformation and the biology of transformed cells (17, mim-1, which is directly activated by the Gag-Myb-Ets protein 29).
    [Show full text]
  • Angiogenic Patterning by STEEL, an Endothelial-Enriched Long
    Angiogenic patterning by STEEL, an endothelial- enriched long noncoding RNA H. S. Jeffrey Mana,b, Aravin N. Sukumara,b, Gabrielle C. Lamc,d, Paul J. Turgeonb,e, Matthew S. Yanb,f, Kyung Ha Kub,e, Michelle K. Dubinskya,b, J. J. David Hob,f, Jenny Jing Wangb,e, Sunit Dasg,h, Nora Mitchelli, Peter Oettgeni, Michael V. Seftonc,d,j, and Philip A. Marsdena,b,e,f,1 aInstitute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada; bKeenan Research Centre for Biomedical Science in the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada; cDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 3E2, Canada; dInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada; eDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; fDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; gArthur and Sonia Labatt Brain Tumour Research Institute, Hospital for SickKids, University of Toronto, Toronto, ON M5G 1X8, Canada; hDivision of Neurosurgery and Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada; iDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; and jDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON M5S 3E5, Canada Edited by Napoleone Ferrara, University of California, San Diego, La Jolla, CA, and approved January 24, 2018 (received for review August 28, 2017) Endothelial cell (EC)-enriched protein coding genes, such as endothelial formation in vitro and blood vessel formation in vivo.
    [Show full text]
  • A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
    www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution.
    [Show full text]
  • The Gli2 Transcription Factor Is Required for Normal Mouse Mammary Gland Development
    Developmental Biology 238, 133–144 (2001) doi:10.1006/dbio.2001.0410, available online at http://www.idealibrary.com on The Gli2 Transcription Factor Is Required for Normal Mouse Mammary Gland Development Michael T. Lewis,*,1,2 Sarajane Ross,*,3 Phyllis A. Strickland,* Charles W. Sugnet,* Elsa Jimenez,* Chi-chung Hui,† and Charles W. Daniel* *Department of Biology, Sinsheimer Laboratories, University of California, Santa Cruz, California 95064; and †The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada The hedgehog signal transduction network performs critical roles in mediating cell–cell interactions during embryogenesis and organogenesis. Loss-of-function or misexpression mutation of hedgehog network components can cause birth defects, skin cancer, and other tumors. The Gli gene family (Gli1, Gli2, and Gli3) encodes zinc finger transcription factors that act as mediators of hedgehog signal transduction. In this study, we investigate the role of Gli2 in mammary gland development. Mammary expression of Gli2 is developmentally regulated in a tissue compartment-specific manner. Expression is exclusively stromal during virgin stages of development but becomes both epithelial and stromal during pregnancy and lactation. The null phenotype with respect to both ductal and alveolar development was examined by transplantation rescue of embryonic mammary glands into physiologically normal host females. Glands derived from both wild type and null embryo donors showed ductal outgrowths that developed to equivalent extents in virgin hosts. However, in null transplants, ducts were frequently distended or irregularly shaped and showed a range of histological alterations similar to micropap- illary ductal hyperplasias in the human breast. Alveolar development during pregnancy was not overtly affected by loss of Gli2 function.
    [Show full text]
  • Supplemental Figure 1 Supplemental Figure 1. Flow Cytometry
    Supplemental Figure 1 Initial neutrophil isolation sample Single cells Live 83.4% 99.6% 99.1% W - SC SC S S FSC FSC FSC-H Live/ dead CD45 positive 100% SC S CD16 PE cy7 CD16 CD45+ CD16+ CD66b+ neutrophils 98.1% CD45 V500 CD16 PerCP cy5.5 Supplemental Figure 1. Flow cytometry with gating strategey depicted confirms 98.1% purity of CD66b/CD16 double positive neutrophils. Supplemental Figure 1. Flow cytometry with gating strategy depicted confirms 98.1% purity of CD66b/CD16 double positive neutrophils. (a) (b) Supplemental Figure 2 A. B. (c) (d) -2000 bp 0 2000bp Position relative to TSS Supplemental Fig 2. a) No response to CpG in qRTPCR. b) Healthy volunteer neutrophils do not produce NETs via sytox green assay in response to pathogen ligands at 1 hour or immediately following live organism challenge supporting this time point for ATAC-seq. (PMA is a positive control)Supplemental(ligand donors Fign=4ure, live 2organism. A. Representativedonors n=2) c) Representative QC plots demonstratingQC plots demonstrating librarylibrary prepprep resultsresults inin expected insert size expecteddistribution and insertd) reads sizeare distributionenriched around andtranscription B. readsstart aresites enriched(TSS). around transcription start sites (TSS). Supplemental Figure 3. LTA BGP LPS HMGB1 FLAG E. coli R848 S. aureus Supplemental Fig 3. Quality control for DiffBind method of identification of differentially accessible regions of chromatin. Correlation heat maps and principal component analysis (PCA) of differentially accessible chromatin. We found that for any given challenge across donors, stimulated samples cluster together, control samples cluster Supplementaltogether, and the stimulated Figandurecontrol 3.cluster Qualityaway from controleach other, forsuggesting DiffBindhigh quality methoddata and accessibleof identificationchromatin region ofidentification differentiallythat allows for analysis accessibleof four healthy donor regionsdata.
    [Show full text]
  • Transcription Regulation of MYB: a Potential and Novel Therapeutic Target in Cancer
    Review Article Page 1 of 11 Transcription regulation of MYB: a potential and novel therapeutic target in cancer Partha Mitra1,2 1Pre-clinical Division, Vaxxas Pty. Ltd. Translational Research Institute, Woolloongabba QLD 4102, Australia; 2Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Woolloongabba QLD 4102, Australia Correspondence to: Partha Mitra. Pre-clinical Division, Vaxxas Pty. Ltd. Translational Research Institute, 37 Kent St., Woolloongabba QLD 4102, Australia; Queensland University of Technology, Translational Research Institute, 37 Kent St., Woolloongabba QLD 4102, Australia. Email: [email protected]; [email protected]. Abstract: Basal transcription factors have never been considered as a priority target in the field of drug discovery. However, their unparalleled roles in decoding the genetic information in response to the appropriate signal and their association with the disease progression are very well-established phenomena. Instead of considering transcription factors as such a target, in this review, we discuss about the potential of the regulatory mechanisms that control their gene expression. Based on our recent understanding about the critical roles of c-MYB at the cellular and molecular level in several types of cancers, we discuss here how MLL-fusion protein centred SEC in leukaemia, ligand-estrogen receptor (ER) complex in breast cancer (BC) and NF-κB and associated factors in colorectal cancer regulate the transcription of this gene. We further discuss plausible strategies, specific to each cancer type, to target those bona fide activators/co-activators, which control the regulation of this gene and therefore to shed fresh light in targeting the transcriptional regulation as a novel approach to the future drug discovery in cancer.
    [Show full text]